OncoMatch/Clinical Trials/NCT05944237
HTL0039732 in Participants With Advanced Solid Tumours
Official title: A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours
Is NCT05944237 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies multiple treatments including HTL0039732 Capsules and HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion for neoplasms.
Treatment: HTL0039732 Capsules · HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion — The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Prostate Cancer
Gastric Cancer
Esophageal Carcinoma
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Pancreatic Cancer
Urothelial Carcinoma
Mesothelioma
Cervical Cancer
Sarcoma
Biomarker criteria
Required: HER2 (ERBB2) mutation/genetic aberration
Required: PIK3CA mutation/genetic aberration
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: EP4 inhibitor
Prior treatment with EP4 inhibitor
Lab requirements
Blood counts
haematological indices within the protocol specified ranges
Kidney function
biochemical indices within the protocol specified ranges
Liver function
biochemical indices within the protocol specified ranges
Haematological and biochemical indices within the protocol specified ranges
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05944237 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EP4 inhibitor disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 mutation/genetic aberration is a required biomarker for enrollment.
Does this trial require PIK3CA?
Yes, PIK3CA mutation/genetic aberration is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify